Literature DB >> 12636177

Treating Alzheimer's disease with cholinesterase inhibitors: what have we learned so far?

Howard Feldman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12636177     DOI： 10.1017/s1041610203008639

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN： 1041-6102            Impact factor:   3.878


× No keyword cloud information.
  3 in total

Review 1.  Development of allosteric modulators of GPCRs for treatment of CNS disorders.

Authors:  Hilary Highfield Nickols; P Jeffrey Conn
Journal:  Neurobiol Dis       Date:  2013-09-27       Impact factor: 5.996

Review 2.  Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.

Authors:  P Jeffrey Conn; Carrie K Jones; Craig W Lindsley
Journal:  Trends Pharmacol Sci       Date:  2009-02-07       Impact factor: 14.819

Review 3.  Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia.

Authors:  Daniel J Foster; Derrick L Choi; P Jeffrey Conn; Jerri M Rook
Journal:  Neuropsychiatr Dis Treat       Date:  2014-01-28       Impact factor: 2.570
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.